Day: December 15, 2022

The agreement expands on an existing partnership and grants Psyence the right to commercialize Filament’s natural psilocybin drug candidate PEX010 25mg within palliative care VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) — Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF) (“Psyence” and, together with Filament, the “Companies”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, today announced the conclusion of a royalty-bearing, worldwide commercial licensing agreement. The agreement grants Psyence the worldwide right to commercialize Filament’s natural psilocybin drug candidate, PEX010 (25 mg), within the context of palliative...

– Inaugural report highlights company’s accomplishments and approach to ESG strategy – PORTLAND, Tenn., Dec. 15, 2022 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of system (“EBOS”) solutions for solar, battery storage, and electric vehicle charging infrastructure, today announced the publication of its 2021 Environmental, Social, and Governance (ESG) Report. The report, which captures data and findings predominantly from the period between January 1st and December 31, 2021, was compiled using a three-step approach to identify, prioritize, and verify ESG risks and opportunities specific to Shoals. This process involved the consideration of widely-accepted ESG frameworks including the Value Reporting Foundation’s Sustainable Accounting Standards...

VERSATILE-002 Phase 2 study investigating PDS0101 in combination with Merck’s KEYTRUDA® (pembrolizumab) in both checkpoint inhibitor refractory and checkpoint inhibitor naïve patients FLORHAM PARK, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced the completion of enrollment in the first stage of the checkpoint inhibitor refractory group of its VERSATILE-002 Phase 2 study for the potential treatment of recurrent and/or metastatic human papillomavirus (HPV16)-positive head and neck cancer. 90% of HPV-associated head and neck cancers in the US are reported to be caused by HPV16, as reported in a study published in the Journal of Clinical Medicine. VERSATILE-002...

Additional reimbursement coverage further expands the market for ProSomnus as the Company seeks to make precision oral appliance therapy a first-line treatment for obstructive sleep apnea SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) — ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision oral appliance therapy (OAT) for the treatment of Obstructive Sleep Apnea (OSA), today announced that its ProSomnus EVO® [PH] Sleep and Snore Device now qualifies for Medicare reimbursement. The Pricing, Data Analysis, and Coding (PDAC) Contractor has reviewed and verified the device for the Healthcare Common Procedure Coding System (HCPCS) code E0486. Medicare beneficiaries account for an estimated 20% of people in the United States with OSA. The ProSomnus EVO [PH] is a precision OAT medical device specifically engineered to meet...

ASHKELON, Israel and VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (C.S.E.: BYND) (“BYND Cannasoft” or the “Company“) today issued a letter to shareholders from its Chief Executive Officer and Director, Yftah Ben Yaackov.  Successful Nasdaq Uplisting On May 31, 2022, BYND Cannasoft was approved for trading on the Nasdaq Capital Market. This listing represents a significant milestone for BYND Cannasoft and enhances our ability to create value for all stakeholders. BYND Cannasoft demonstrated that a strong business plan and an efficient operational approach helped us drive the listing process forward. The Nasdaq listing has already helped us increase liquidity, which should, in turn, drive down the cost of capital to execute our business plan....

Joint Venture Seeks to Expand ELT’s Current Reach into New Markets; Expand ELT’s Existing Vehicle Fleet, Convert Fleet Vehicles Using Principal Partner’s EV/Hybrid Technologies, and Generate Near-Term Revenue DALLAS, TEXAS, Dec. 15, 2022 (GLOBE NEWSWIRE) — Principal Solar, Inc. (OTC Pink: PSWW) (“Principal” or “the Company”), a strategic investor in organizations and technologies that support next- generation opportunities in traditional, renewable, and clean energy sectors as well as an investor in and operator of undervalued petroleum-producing properties, today announced that it has entered into a Joint Venture Agreement (the “Agreement”) with Executive Logistics & Transportation (“ELT”) for the purpose of expanding ELT’s existing logistics operations into new markets beyond its current activities in Tennessee and the Southeastern...

The Company’s publicly traded warrants ticker will also change from ‘STRNW’ to ‘SWAGW’ Quincy, MA, Dec. 15, 2022 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: STRN) (NASDAQ: STRNW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today announced that the Company’s common stock will begin trading on Nasdaq under the ticker symbol “SWAG” on December 16, 2022. This ticker symbol will replace the Company’s current ticker symbol for its common stock, “STRN”. Additionally, the Company’s publicly traded warrants to purchase common stock will begin trading under the ticker symbol “SWAGW” on December 16, 2022. This ticker symbol will replace the Company’s current ticker symbol for its publicly traded...

BANNOCKBURN, Ill., Dec. 15, 2022 (GLOBE NEWSWIRE) — Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent national provider of home and alternate site infusion services, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 in San Francisco. John Rademacher, Chief Executive Officer, and Mike Shapiro, Chief Financial Officer, are scheduled to present at 9:00am PT. Webcast links and related presentation materials will be available online at https://investors.optioncarehealth.com. About Option Care Health Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with...

False Creek Neighbourhood Energy Utility Selects Five SHARC Systems for its existing wastewater energy transfer capacity and ongoing expansionWatch Mike Harcourt, former Premier of British Columbia & former Mayor of Vancouver, as he talks about the impact of using the forgotten power of wastewater as a clean energy source.He touches on how including wastewater in clean energy plans can have a massive effect on cities, municipalities and ultimately the world.For more info visit www.SHARCenergy.comSHARC System Picture of SHARC system at City of Vancouver NEUVANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company“), a world leader in wastewater energy transfer (“WET”), is...